Nasdaq:ASMB
ASSEMBLY BIOSCIENCES, INC.
A biotechnology firm commercializing antibody therapies via strategic partnerships, showing recent revenue growth but operating at a significant net loss.
Key Metrics
Investment Thesis
Bull Case
The recent surge in revenue to $28.5M demonstrates successful commercialization of the company's antibody platform, potentially signaling a turning point toward sustainable growth. The reduction in net loss year-over-year suggests improving operational efficiency despite heavy R&D investments totaling $55.9M. Strategic partnerships likely provide a stable revenue base that could support future profitability without requiring massive capital expenditures.
Bear Case
The company continues to operate at a significant deficit with a retained earnings deficit exceeding $825M, creating an urgent need for further fundraising and potential equity dilution. Heavy reliance on external financing is evident with cash flow from operations of $-51.1M against total liabilities of $85.8M. Without a clear path to profitability or major milestone payments, the high burn rate poses a severe threat to liquidity in the current market environment.
About ASSEMBLY BIOSCIENCES, INC.
Assembly Biosciences is a biotechnology company focused on developing advanced therapeutic antibodies and immuno-oncology solutions, primarily serving the pharmaceutical and biotech markets in the United States. The company leverages its proprietary antibody discovery platform to generate revenue through product sales and licensing agreements with industry partners.
Analysis
Management Discussion
While the company achieved a notable 394% increase in revenue from $7.2M in 2023 to $28.5M in 2024, this growth occurred alongside a narrowing net loss of $40.2M compared to $61.2M the prior year. However, the substantial operating expenses of $73.9M and high R&D spending indicate that profitability remains elusive as the firm scales its commercialization efforts. Cash flow from operations was negative at $-51.1M, suggesting that revenue growth has not yet translated into positive cash generation from core business activities.
Industry Overview
The biotechnology industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles, yet offers substantial returns upon successful drug approvals. Companies in this sector often rely heavily on licensing agreements and strategic partnerships to commercialize discoveries while minimizing capital risk. Market dynamics are currently shaped by the demand for innovative immuno-oncology therapies amidst a competitive landscape of established pharmaceutical giants.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $7.2M | $28.5M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $7.2M | $28.5M |
| Operating Expenses | $94.1M | $71.8M | $73.9M |
| Operating Income | $-94.1M | $-64.6M | $-45.4M |
| R&D | $70.0M | $48.9M | $55.9M |
| G&A | $24.1M | $22.9M | $18.0M |
| Stock-Based Comp | $6.6M | $5.1M | $3.1M |
| D&A | $498.0K | $450.0K | $129.0K |
| Depreciation | $500.0K | $500.0K | — |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $1.0M | $3.5M | $5.6M |
| Interest Income | $1.0M | $3.5M | $5.6M |
| Pre-Tax Income | $-93.1M | $-61.2M | $-39.8M |
| Income Tax | $0 | $33.0K | $330.0K |
| Continuing Ops | $-93.1M | $-61.2M | $-40.2M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-93.1M | $-61.2M | $-40.2M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-93.1M | $-61.2M | $-40.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $97.0M | $133.8M | $115.5M |
| Cash & Equivalents | $52.4M | $19.8M | $38.3M |
| Accounts Receivable | $944.0K | $43.0K | $0 |
| Prepaid Expenses | $4.4M | $3.5M | $3.4M |
| Other Current Assets | $39.2M | $110.4M | $73.7M |
| Long-Term Assets | $4.8M | $3.0M | $3.7M |
| PP&E (Net) | $743.0K | $385.0K | $284.0K |
| Operating Leases | $3.2M | $2.3M | $3.1M |
| Other LT Assets | $889.0K | $312.0K | $312.0K |
| Total Assets | $101.8M | $136.8M | $119.2M |
| Current Liabilities | $16.3M | $39.2M | $47.8M |
| Accounts Payable | $2.5M | $461.0K | $585.0K |
| Current Leases | $3.4M | $1.2M | $461.0K |
| Deferred Revenue | — | $30.9M | $37.6M |
| Other Current Liab | $3.1M | $885.0K | $2.3M |
| Long-Term Liabilities | $2.8M | $56.5M | $38.0M |
| LT Operating Leases | $101.0K | $1.1M | $2.6M |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $19.1M | $95.7M | $85.8M |
| Shareholders' Equity | $82.7M | $41.1M | $33.4M |
| Retained Earnings | $-724.5M | $-785.7M | $-825.9M |
| AOCI | $-803.0K | $-81.0K | $-211.0K |
| Total L&E | $101.8M | $136.8M | $119.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-93.1M | $-61.2M | $-40.2M |
| Non-Cash Adjustments | $9.9M | $6.4M | $1.2M |
| Working Capital Changes | $-1.2M | $77.6M | $-12.2M |
| Cash from Operations | $-84.5M | $22.7M | $-51.1M |
| Capital Expenditures | $102.0K | $255.0K | $28.0K |
| Cash from Investing | $90.6M | $-69.1M | $40.2M |
| Cash from Financing | $614.0K | $13.8M | $29.4M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $6.8M | $-32.6M | $18.5M |
| Beginning Cash | $45.6M | $52.4M | $19.8M |
| Ending Cash | $52.4M | $19.8M | $38.3M |
Frequently Asked Questions
How does ASSEMBLY BIOSCIENCES, INC. make money?
Antibody Discovery and Development: Utilizing proprietary platforms to identify novel therapeutic targets for oncology indications. Commercialization and Licensing: Generating gross profit of $28.5M through sales and licensing deals with third-party partners. Clinical Operations: Managing ongoing research and development programs, evidenced by the $55.9M allocated to R&D expenses.
What are the main risks for ASMB?
Significant Operating Losses: The company reported a net loss of $40.2M in 2024, raising concerns about long-term cash burn sustainability. Revenue Concentration: Gross profit is heavily dependent on specific licensing deals, creating vulnerability to partner negotiations or deal terminations. Dilution Risk: With substantial financing inflows ($29.4M from operations) and a retained earnings deficit of over $825M, future equity issuances may dilute existing shareholders. Regulatory Uncertainty: Delays in clinical trials or FDA approvals for their therapeutic antibodies could severely impact future revenue projections.
What is ASMB's competitive advantage?
Proprietary Antibody Platform: A unique technology stack enabling rapid identification and optimization of high-potential therapeutic candidates. Strategic Partnership Pipeline: Strong relationships with major pharmaceutical partners facilitating commercialization without heavy capital expenditure on manufacturing. Experienced Management Team: Leadership with deep expertise in navigating the complex regulatory and commercial landscape of biotechnology.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.